GPT Healthcare DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.78×0.77×0.72×0.70×
0.96×0.96×1.08×0.97×
12.9%12.1%15.8%17.5%
1.11×1.11×1.12×1.16×
1.72×1.72×1.55×1.58×
18.4%17.1%21.3%21.9%
16.3%16.3%21.4%21.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

GPTHEALTH₹136.89

GPT Healthcare Limited

· Pharma & Health
₹ CrorePeersGKSLSHALBYINDRAMEDCOLOTUSEYEARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹1,123 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.700.720.770.78
Interest Burden (Pretax/EBIT) ×0.971.080.960.96
EBIT Margin %17.4615.8012.0812.86
Asset Turnover ×1.161.121.111.11
Financial Leverage (Assets/Equity) ×1.581.551.721.72
ROE (5-step product, year-end total equity) %21.9021.2917.1118.41
ROE (owners' profit / average owners' equity) %21.8621.4116.3216.32
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.